B+
Bull case
25%
Probability
Target price
$145.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
ICUI
ICU MedicalDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$118.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$102.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+32.1
Score
AI commentary
As of May 9, 2026, the near-term tone is mixed-to-cautious: the company delivered a modest earnings beat on May 7, 2026, and checked market coverage showed a positive same-day reaction of about 2.9%, but the move was not large enough to prove a thesis reset, and delayed analyst revision evidence remained thin in checked sources. With strong primary filing context but only moderate forward catalyst density and a negative deterministic prior, this still reads more like a post-earnings monitoring setup than a high-conviction bullish inflection.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystQ1 earnings beat produced only a modest initial reratingMedium impact
On May 7, 2026, ICU Medical reported Q1 revenue of $530.2 million, adjusted EPS of $1.97, GAAP gross margin of 39%, and said results were generally in line with expectations; AP/Zacks-reported consensus cited in checked coverage was $519.9 million revenue and $1.78 adjusted EPS, while MarketScreener showed the stock closed at $123.07, up 2.91% that day, implying the beat did not fully change the narrative yet [#8-K-2026-05-07].
2026-08-06catalystCore Consumables and Infusion Systems growth can offset divestiture noise if sustainedHigh impact
Q1 2026 Consumables revenue rose to $278.3 million and Infusion Systems revenue rose to $179.6 million; the 10-Q says Consumables growth was driven primarily by new customer installations and increased demand for Infusion Consumables and Oncology, while the press release said organic revenue increased 1% excluding the IV Solutions divestiture and FX [#10-Q-2026-05-07] [#8-K-2026-05-07].
2026-12-31eventFDA pump remediation and 510(k) resubmission remain unresolved overhangsHigh impact
The March 31, 2026 10-Q says ICU Medical withdrew 510(k) applications for next-generation MedFusion and updated CADD pumps after FDA requests for additional testing and is planning to resubmit as soon as possible; until the 2025 warning-letter matters are resolved to FDA satisfaction, the company says additional legal or regulatory action may occur and no loss contingency is recorded because the impact cannot yet be predicted [#10-Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology